Rate this post

  • MedMen and PharmaCann terminate enterprise mixture settlement
  • At the side of the termination, MedMen can be compensated with retail and cultivation belongings in Illinois and Virginia
  • Termination opens up MedMen’s stability sheet to deepen presence in core retail markets of California, Illinois, Nevada, Florida, New York and Massachusetts and make investments additional in its omni-channel platform
  • Appoints Zeeshan Hyder as Chief Monetary Officer, efficient instantly


October 08, 2019 06:00 AM Jap Daylight Time

LOS ANGELES–(BUSINESS WIRE)–MedMen Enterprises Inc. (CSE: MMEN) (OTCQX: MMNFF) (“MedMen” or the “Firm”), a number one cannabis retailer with operations throughout the U.S., right now introduced the mutual settlement to terminate the Enterprise Mixture Settlement dated December 23, 2018, pursuant to which MedMen was to amass PharmaCann, LLC (“PharmaCann”) in an all-stock transaction (“Transaction”). In mild of market developments over the previous 12 months and the continued evolution of its enterprise technique, MedMen and its Board have decided that specializing in leveraging the Firm’s retail model, its management place in California, and its digital platform to develop the enterprise will create larger shareholder worth than the completion of the Transaction. In reference to the termination, PharmaCann has agreed to switch sure cannabis licenses and associated belongings in Illinois and Virginia to MedMen for no further consideration from MedMen, aside from the forgiveness of sure debt, as additional described beneath.

“Trying on the PharmaCann portfolio right now, Illinois has emerged as probably the most enticing alternative for our longer-term, strategic development plan. The addition of these belongings, with out dilution, is a win for MedMen and our shareholders.”

Tweet this

“The cannabis sector has developed tremendously since we first introduced the PharmaCann transaction and primarily based on the present macro-environment and future alternatives that exist for our enterprise, we imagine it’s now in the most effective curiosity of our shareholders to deepen, fairly than widen, our Firm’s attain,” mentioned Adam Bierman, MedMen co-founder and chief govt officer. “Trying on the PharmaCann portfolio right now, Illinois has emerged as probably the most enticing alternative for our longer-term, strategic development plan. The addition of these belongings, with out dilution, is a win for MedMen and our shareholders.”

On December 24, 2018, MedMen introduced that it had entered into the definitive settlement to amass PharmaCann, through which PharmaCann unitholders have been anticipated to obtain roughly 168.four million shares within the mixed firm, primarily based on MedMen’s totally diluted shares excellent as of June 29, 2019. Because the announcement, a number of {industry} developments have considerably impacted the accretive nature of the Transaction, together with the next:

  • The capital markets, each for the U.S. and Canadian cannabis industries, have shifted since March 2019, with the HMMJ index down 47%1 throughout that point interval. The underperformance has made it more and more extra essential to allocate capital effectively given the present {industry} headwinds. Whereas PharmaCann holds a number of licenses throughout the U.S., a big portion of its belongings, notably associated to cultivation and manufacturing in medical markets, require vital capital expenditures.
  • Over the previous six months, MedMen has determined to more and more concentrate on California, the place there stays vital upside for cannabis operators. Roughly 76%2 of California cities proceed to ban leisure cannabis. A number of jurisdictions inside the state not too long ago introduced the graduation of leisure gross sales, and the Firm has been actively making use of for, buying and constructing out retail areas throughout the state, the place it’s licensed for 17 shops. MedMen plans to have 30 shops within the state by the tip of calendar yr 2020. Given the worth MedMen has created in California, the Firm doesn’t imagine entry into non-core markets is definitely worth the diploma of shareholder dilution required by the Transaction.
  • The closing timeline for the Transaction was considerably impacted given regulatory hurdles on the federal and state degree, which delayed the combination and realization of synergies that have been initially factored into the worth of the Transaction to the Firm.
  • Along with increasing its retail footprint, MedMen believes allocating capital and assets in direction of enhancing its omni-channel providing in its core markets, by its supply and loyalty platforms, will create extra long-term shareholder worth than getting into new medical markets, corresponding to Pennsylvania, Ohio and Maryland, the place the Firm doesn’t at present have working leverage.

As a part of the settlement to terminate, PharmaCann has agreed to pay a termination payment to MedMen by a switch of the membership pursuits (“Switch of Pursuits”) in three entities holding the next 4 belongings:

  • Operational cultivation and manufacturing facility in Hillcrest, Illinois
  • Retail location in Evanston, Illinois
  • Retail license for Larger Chicago, Illinois
  • License for vertically built-in facility in Virginia

On a professional forma foundation, MedMen could have licenses for 4 retail areas in Larger Chicago, together with its current location in Oak Park, Illinois. The Firm may also maintain considered one of solely 213 cultivation and manufacturing licenses within the state, which can enable MedMen to vertically combine and have full management of its provide chain as soon as leisure gross sales start in January 2020. As a part of the settlement to terminate and contingent on the profitable Switch of Pursuits, MedMen will forgive all quantities excellent below its current line of credit score to PharmaCann (the “Line of Credit score”), which totaled roughly US$21 million, together with accrued curiosity, as of September 30, 2019. Within the occasion any Switch of Curiosity is unable to happen resulting from a ultimate adjudication or denial by the relevant regulatory physique governing such license (a “Rejected Switch”), PharmaCann can pay MedMen an quantity equal to (i) one-third (1/3) of the mixture principal quantity and any corresponding accrued curiosity thereon owed below the Line of Credit score (such curiosity to be calculated as if no mortgage forgiveness of any portion of the Line of Credit score occurred), and (ii) US$10 million (such quantities are collectively known as the “Rejected Switch Price”) for every denial. Any such Rejected Switch Price shall be paid inside 5 days of the associated Rejected Switch, or, PharmaCann could elect to finance the Rejected Switch Price, supplied that the financed Rejected Switch Price shall accrue curiosity at a charge of seven and one-half p.c (7.5%) each year and be due and payable on the primary anniversary of the date of the Rejected Switch.

Moreover, efficient right now, Zeeshan Hyder has been appointed Chief Monetary Officer at MedMen. Mr. Hyder, at present MedMen’s Chief Company Improvement Officer, has been an integral a part of the management staff at MedMen since 2017, overseeing company improvement, investor relations and different monetary development initiatives. His understanding of the corporate’s strategic plan and deep data of the cannabis {industry} present a superb basis for continued fiscal success. To this point, Mr. Hyder has led over $300M in M&A offers executed, partnered with the CEO to take the corporate public and raised $500M in capital for direct funding into the enterprise.

Mr. Hyder, alongside MedMen’s CEO and Board, has seen the enterprise by an essential chapter and can be instrumental in spearheading the corporate’s path in direction of profitability. MedMen is concentrating on break even EBITDA by the tip of calendar 2020 and can present additional particulars on the October 28th earnings name.

Hyder succeeds Michael Kramer, whose employment has been terminated as of October 7, 2019. Mr. Kramer will concentrate on a seamless transition and as such has signed a consulting settlement for the rest of the calendar yr.

1 Supply: Bloomberg; represents time interval between March 19, 2019 and September 30, 2019
2 Supply: https://www.latimes.com/california/story/2019-08-14/californias-biggest-legal-marijuana-market
3 Supply: https://www2.illinois.gov/websites/agr/Crops/MCPP/Pages/default.aspx

About MedMen:

Based in 2010, MedMen is North America’s premium cannabis retailer. Founders Adam Bierman and Andrew Modlin have outlined the following era discovery platform for cannabis and all its advantages. A sturdy choice of high-quality merchandise, together with MedMen-owned manufacturers [statemade], LuxLyte and MedMen Crimson, coupled with a staff of cannabis-educated associates cement the Firm’s dedication to offering an unparalleled expertise. MedMen’s industry-leading expertise permits a completely compliant, owned-and-operated supply service and MedMen Buds, a nationwide loyalty program.

MedMen believes {that a} world the place cannabis is authorized and controlled is safer, more healthy and happier. Be taught extra at www.MedMen.com.

SOURCE: MedMen Enterprises

Cautionary Observe Relating to Ahead-Trying Data and Statements:

This press launch incorporates sure “forward-looking data” inside the that means of relevant Canadian securities laws and may include statements that will represent “forward-looking statements” inside the that means of the protected harbor provisions of america Non-public Securities Litigation Reform Act of 1995, 15 U.S.C.A. Sections 77z-2 and 78u-5 (Supp. 1996). Such forward-looking data and forward-looking statements will not be consultant of historic information or data or present situation, however as an alternative symbolize solely MedMen’s beliefs relating to future occasions, plans or targets, a lot of which, by their nature, are inherently unsure and outdoors of MedMen’s management. Typically, such forward-looking data or forward-looking statements will be recognized by way of forward-looking terminology corresponding to “plans”, “expects” or “doesn’t anticipate”, “is anticipated”, “funds”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “doesn’t anticipate”, or “believes”, or variations of such phrases and phrases or could include statements that sure actions, occasions or outcomes “could”, “may”, “would”, “may” or “can be taken”, “will proceed”, “will happen” or “can be achieved”. The forward-looking data and forward-looking statements contained herein could embrace, however will not be restricted to, the anticipated advantages from terminating the Transaction, expectations relating to the Switch of Pursuits, together with the power to finish such asset transfers, expectations relating to the receipt from PharmaCann of Rejected Switch Charges within the occasion of any Rejected Switch, expectations relating to the variety of areas to be working in California by the tip of calendar yr 2020, and expectations for different financial, enterprise, and/or aggressive elements.

By figuring out such data and statements on this method, MedMen is alerting the reader that such data and statements are topic to identified and unknown dangers, uncertainties and different elements that will trigger the precise outcomes, degree of exercise, efficiency or achievements of MedMen to be materially completely different from these expressed or implied by such data and statements. As well as, in reference to the forward-looking data and forward-looking statements contained on this press launch, MedMen has made sure assumptions. Among the many key elements that might trigger precise outcomes to vary materially from these projected within the forward-looking data and statements are the next: incapability to obtain the requisite regulatory approvals for the Switch of Pursuits, incapability of PharmaCann to pay any Rejected Switch Charges that will come up because of a number of Rejected Transfers, modifications basically financial, enterprise and political situations, together with modifications within the monetary markets; modifications in relevant legal guidelines and compliance with intensive authorities regulation. Ought to a number of of those dangers, uncertainties or different elements materialize, or ought to assumptions underlying the forward-looking data or statements show incorrect, precise outcomes could fluctuate materially from these described herein as supposed, deliberate, anticipated, believed, estimated or anticipated.

Though MedMen believes that the assumptions and elements utilized in making ready, and the expectations contained in, the forward-looking data and statements are affordable, undue reliance shouldn’t be positioned on such data and statements, and no assurance or assure will be on condition that such forward-looking data and statements will show to be correct, as precise outcomes and future occasions may differ materially from these anticipated in such data and statements. The forward-looking data and forward-looking statements contained on this press launch are made as of the date of this press launch, and MedMen doesn’t undertake to replace any forward-looking data and/or forward-looking statements which might be contained or referenced herein, besides in accordance with relevant securities legal guidelines. All subsequent written and oral forward-looking data and statements attributable to MedMen or individuals appearing on its behalf is expressly certified in its entirety by this discover.

The publish MedMen Broadcasts Termination of Merger Settlement With PharmaCann and Administration Adjustments appeared first on L.A. Hashish Information.